Recruiting

Next Generation Delivery System

Sponsor:

Varian, a Siemens Healthineers Company

Code:

NCT07824583

Conditions

Lung Cancer (Diagnosis)

Liver Cancer, Adult

Pancreatic Cancer

Thoracic Cancers

Abdominal Cancer

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

Next Generation Delivery System (NGDS)

Study Details

Brief summary:

The purpose of this research is to evaluate the "Next Generation Delivery System" (NGDS) and determine if this machine will be more efficient at delivering radiation in shorter treatment time and better patient tolerance, with less breath holding.

Conditions

Lung Cancer (Diagnosis)

Liver Cancer, Adult

Pancreatic Cancer

Thoracic Cancers

Abdominal Cancer

Study ID

NCT07824583

Start date

Jul 31, 2026

Status verified date

Sep, 2026

Completion date

May, 2027

Anticipated

Primary completion date

Feb, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Target lesions in the thorax or upper abdomen
2. Planned to undergo SBRT radiation treatment delivered on a conventional "C-arm" or ring gantry CBCT guided linear accelerator under breath hold conditions
3. ECOG performance status 0-1
4. At least 21 years of age
5. Able to sign informed consent

Exclusion Criteria:

1. Participants enrolled in another clinical investigation the investigator believes to be in conflict with this clinical investigation.
2. Participants with any other medical condition or laboratory value that would, at the discretion of the investigator, preclude the patient from participation in this clinical investigation.

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Device Feasibility

Interventions and Outcome Measures

Arms

other: Single Arm - All patients will be treated the same

"Mock" treatment on the NGDS machine.

Interventions

Next Generation Delivery System (NGDS)

Participant will receive a "mock" treatment on the NGDS machine. Participant will complete experience questionnaires.

Primary outcome measure

  • To evaluate the feasibility of the mock NGDS DMAT workflow under breath hold conditions. [ Time Frame: From enrollment to end of "mock" treatment of last participant enrolled, assessed up to 6 months ]

Central Contacts and Locations

Central contacts

Jennifer Woo

437-991-3496jennifer.woo@siemens-healthineers.com

Locations

Siteman Cancer Center Washington University

Recruiting

St Louis, Missouri, United States, 63108

Principal Investigator:

Pamela Samson

University Hospital Cleveland Medical Center

Recruiting

Cleveland, Ohio, United States, 44106

Contacts

Carly Croyle, BS

216-844-7087Carly.Croyle@UHhopsitals.org

Principal Investigator:

Lauren Henke

More Information

Sponsor

Varian, a Siemens Healthineers Company

Last update posted

Sep 17, 2026

Last verified

Sep, 2026

Keywords

  • Stereotactic body radiation therapy
  • Lung cancer
  • Liver cancer
  • Pancreatic cancer
  • Thoracic cancer
  • abdominal cancer
  • Breath hold
  • DMAT
  • linac
  • motion monitoring
  • linear accelerator
  • kV fluoroscopy
  • C-arm

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-18. This information was provided to ClinicalTrials.gov by Varian, a Siemens Healthineers Company on 2026-09-17.